Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117 in advanced solid tumors
NCT05940116Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-20117-2 in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 28 days, Maximum Applicable Dose at 28 days and 1 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
HS-20117-2
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05940116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940116.